Cardlytics CFO reports 117,930-share initial holding
Cardlytics, Inc. filed a Form 3 showing its new Chief Financial Officer, Evans David Thomas, as a beneficial owner of company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cardlytics, Inc. filed a Form 3 showing its new Chief Financial Officer, Evans David Thomas, as a beneficial owner of company stock. As of the event date of January 12, 2026, he beneficially owns 117,930 shares of Cardlytics common stock held directly. The filing does not list any derivative securities such as options or warrants. This establishes his initial reportable ownership position as an officer of the company.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Stock | -- | -- | -- |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Form 3 filing for CDLX disclose?
Does the Cardlytics CFO report any derivative securities on this Form 3?
What is the event date for the Cardlytics (CDLX) Form 3 ownership report?
What is the role of the reporting person in the Cardlytics Form 3?
AI-generated analysis. How Rhea-AI works. Not financial advice.